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ly. Forty-nine patients (77%) spent  1 10% of the night with 
Sp O 2  ! 90% (desaturators), and 33 (52%) spent  1 50% of the 
night with Sp O 2  ! 90% (sustained desaturators). The positive 
predictive values of daytime Sp O 2  1 90% for being a noctur-
nal nondesaturator or sustained nondesaturator were 25 
and 53%, respectively. Nocturnal Sp O 2 was negatively corre-
lated with the tricuspid pressure gradient, but not with func-
tional class, 6-min walk test, or pro-BNP.  Conclusions: Noc-
turnal hypoxemia is very common in PAH and CTEPH despite 
often normal daytime Sp O 2 and reflects disease severity. 
Nocturnal pulse oximetry should be considered in the rou-
tine evaluation of pPH patients and research should be di-
rected toward the treatment of nocturnal desaturation in 
pPH.  Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Precapillary pulmonary hypertension (pPH) is de-
fined as a resting mean pulmonary artery pressure  6 25 
mm Hg along with a pulmonary capillary wedge pressure 
 ^  15 mm Hg. In the absence of relevant lung diseases, 
the two major groups are pulmonary arterial hyperten-
sion (PAH), including idiopathic and associated forms, 
 Key Words 
 Chronic thromboembolic pulmonary hypertension   
Pulmonary arterial hypertension   Sleep disordered 
breathing 
 Abstract 
 Background: Nocturnal hypoxemia is important in precapil-
lary pulmonary hypertension (pPH) as it worsens pulmonary 
hemodynamics. Whether daytime oxygen saturation (Sp O 2 ) 
predicts nocturnal hypoxemia in pPH patients has not been 
conclusively studied.  Objectives: To investigate the preva-
lence of nocturnal hypoxemia in comparison to daytime 
Sp O 2 and disease severity in ambulatory patients with pul-
monary hypertension.  Methods: Consecutive patients diag-
nosed with pPH classified as either pulmonary arterial (PAH) 
or chronic thromboembolic pPH (CTEPH) had daytime rest-
ing and exercise Sp O 2 (at the end of a 6-min walk test); there-
after, they underwent overnight pulse oximetry at home. 
Functional class, pro-brain natriuretic peptide (pro-BNP) and 
the tricuspid pressure gradient were assessed.  Results: Six-
ty-three patients [median (quartiles) age 62 (53; 71), 43 fe-
males] with PAH (n = 44) and CTEPH (n = 19) were included. 
The resting Sp O 2 , exercise Sp O 2 , and mean nocturnal Sp O 2 
were 95% (92; 96), 88% (81; 95), and 89% (85; 92), respective-
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and chronic thromboembolic pulmonary hypertension 
(CTEPH)  [1, 2] . Despite major advances in therapy over 
the last two decades, pPH remains a progressive and in-
curable condition with the exception of those CTEPH pa-
tients who are eligible for surgery  [3–6] . Sleep reduces 
respiratory drive and airway stability and may therefore 
lead to alveolar hypoventilation and ventilatory instabil-
ity with apnea/hypopnea associated with intermittent or 
sustained hypoxemia. Previous studies have shown that 
nocturnal hypoxemia is common in patients with PAH, 
with more than two thirds of patients affected  [7, 8] . Hy-
poxia induces pulmonary vasoconstriction via its effects 
on pulmonary vascular smooth muscle and endothelial 
cells and therefore may lead to elevated pulmonary artery 
pressure  [9] . This effect has been shown even in transient 
hypoxia  [10] . Improved functional capacity and survival 
have been demonstrated with long-term oxygen therapy 
in hypoxemic patients with chronic obstructive pulmo-
nary disease (COPD)  [11, 12] . Supplemental oxygen can 
improve elevated pulmonary arterial pressure in mild 
pPH  [13, 14] . Previous studies have shown that over a 
third of patients with right heart failure due to pPH suffer 
from Cheyne-Stokes respiration/central sleep apnea  [15, 
16] , similar to patients with left ventricular heart failure. 
In left heart failure, noninvasive positive pressure ventila-
tion or oxygen might be effective therapies as adjuncts to 
drug treatment  [17] ; however, studies in pPH are lacking. 
Other reasons for reduced nocturnal oxygen saturation 
(Sp O 2 ) might be an increased ventilation perfusion mis-
match and impairment of respiratory muscle efficiency 
due to the recumbent position.
 In order to better define the role of nocturnal hypox-
emia in pPH not associated with lung diseases, we per-
formed nocturnal pulse oximetry in a cohort of outpa-
tients with PAH or CTEPH in their homes and compared 
the results to daytime office measurements at rest and 
during exercise, and to pulmonary hemodynamics and 
functional status. We hypothesized that low nocturnal 
Sp O 2 would be associated with impaired hemodynamics 
and poor functional status and that daytime Sp O 2 would 
not reliably predict nocturnal desaturation.
 Methods 
 Patients 
 Consecutive patients diagnosed with PAH or CTEPH at our 
tertiary care outpatient clinic who were not using supplemental 
oxygen were eligible for enrolment upon written informed con-
sent from 2007 to March 2011. The study was approved by the lo-
cal ethical review board. All patients were diagnosed according to 
current guidelines and had undergone right heart catheterization 
at the time of the initial evaluation. At the time of this study, they 
were in stable condition and had been on the same therapy for at 
least 1 month.
 Assessments 
 Weight and height were measured and the WHO functional 
class was assessed. The tricuspid pressure gradient was assessed 
by echocardiography  [18] . After a rest period of  6 10 min in a 
comfortable sitting position, patients underwent measurements 
of blood pressure, pulse rate, and resting Sp O 2 by pulse oximetry 
using a finger probe (Pulsox-300i; Anandic Medical Systems, 
Switzerland). Patients subsequently performed a 6-min walk test 
(6MWT) according to standard guidelines and Sp O 2 was moni-
tored continuously. The lowest Sp O 2 during the 6MWT was noted 
as the exercise Sp O 2  [19] . N-terminal pro-brain natriuretic peptide 
(NT-pro-BNP) was measured in a venous blood sample.
 Ambulatory nocturnal pulse oximetry was performed by fit-
ting a finger probe and an oximeter to the patient’s wrist (Pul-
soxi-300i; Anandic Medical Systems, or Vivo Metrics, Ventura, 
Calif., USA) and giving thorough instructions to wear it over-
night at home. Patients were advised to mark their lights-off time 
in the evening and lights-on time in the morning and any spe-
cific events during the night in a symptom log. Patients returned 
the pulse oximeter the next day and data were downloaded for 
analysis. The first 32 patients had additional ambulatory respira-
tory polygraphy (LifeShirt, Vivo Metrics) as previously described 
 [15, 20] . 
 Data Analysis and Statistics 
 Desaturation during the 6MWT was defined as a decrease in 
Sp O 2  6 4% and below 90%. Nocturnal pulse oximetry was ana-
lyzed from lights-off to lights-on as time in bed (TIB). The mean 
nocturnal Sp O 2 and the percent of TIB spent with Sp O 2  ! 90% were 
derived. Patients who had spent  1 10% of the TIB with Sp O 2  ! 90% 
were classified as desaturators. Among these, patients who had 
spent  1 50% of the TIB with Sp O 2  ! 90% were classified as sus-
tained desaturators. The oxygen desaturation index was comput-
ed as the number of desaturations  6 4%/h. Ambulatory cardiore-
spiratory sleep studies were obtained in a subset of patients and 
analyzed as previously described  [15] . Data are presented as me-
dians (quartiles) and were compared using the Mann-Whitney U 
test, the Kruskal-Wallis test, and Fisher’s exact test. Pearson’s cor-
relation and logistic regression were used to evaluate associations 
between continuous variables. Statistical tests were two-tailed 
and p  ! 0.05 was considered statistically significant. 
 Results  
 Patients 
 Sixty-three pPH patients were included in the study 
( table 1 ). Slightly more than half of the patients suffered 
from idiopathic PAH, a third from CTEPH, and the re-
mainder from other associated PAH  [1] . Patients were in 
WHO functional classes II–IV and had a moderately re-
duced 6MWT and a markedly increased tricuspid pres-
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sure gradient. Patients were on endothelin receptor an-
tagonists (n = 41), phosphodiesterase-5 inhibitors (n = 35), 
and prostanoids (n = 14) according to current guidelines 
 [18] . 
 Pulse Oximetry Data and Sleep Studies 
 Results of the daytime and nocturnal oximetries of all 
patients and the additional home respiratory polygraphy 
in 32 patients are shown in  table 2 . In our cohort of pa-
tients who were not using supplemental oxygen, the me-
dian daytime resting Sp O 2 was in the normal range [95 
(92; 96)], with only 8 patients having a resting Sp O 2  ^  90%. 
The exercise Sp O 2 was significantly lower and over half of 
patients desaturated by  6 4% to values  ! 90%.
 Nocturnal pulse oximetry revealed a median Sp O 2 
during TIB of 89% (85; 92), with 49 of 63 patients (78%) 
spending  1 10% of the time with an Sp O 2  ! 90% (desatura-
tors). Thirty-three of these (52% of the entire cohort) 
spent  1 50% of the TIB with Sp O 2  ! 90% (sustained de-
saturators). The severity distribution of nocturnal desat-
urators is shown in  figure 1 . We found no difference in 
patients’ characteristics or daytime or nocturnal Sp O 2 be-
tween PAH and CTEPH.
 Association between Daytime and Nocturnal 
Assessments 
 Baseline characteristics of nocturnal nondesaturators, 
desaturators, and sustained desaturators are shown in  ta-
ble  3 . Desaturators had significantly higher tricuspid 
pressure gradients and a significantly lower exercise Sp O 2 
along with greater exercise desaturation compared to 
nondesaturators, and the proportion of patients with 
sleep apnea (defined as an apnea/hypopnea index  6 10/h 
or  6 10/h oxygen desaturations) was also higher among 
desaturators. 
 We found significant correlations between the day-
time resting and exercise Sp O 2 and the mean nocturnal 
Sp O 2 (r = 0.491 and r = 0.452, p  ! 0.001 in both instances; 
 fig. 2 a, b). The tricuspid pressure gradient correlated neg-
atively with the mean nocturnal Sp O 2 and positively with 
the time spent with an Sp O 2  ! 90% (r = –0.349 and r = 
0.346, p = 0.007 and p = 0.008;  fig. 3 a, b). Multiple regres-
sion analysis with the nocturnal Sp O 2 as the dependent 
factor and age, BMI, 6MWT, pro-BNP, tricuspid pressure 
gradient, and resting and exercise Sp O 2 as independent 
factors revealed that only daytime resting Sp O 2 and the 
tricuspid pressure gradient were independently correlat-
ed with the mean nocturnal Sp O 2 [p = 0.018 and p = 0.003, 
standardized coefficient B (95% CI) 0.321 (0.073–0.744) 
and –0.403 (–0.112 to 0.025)]. We did not find a signifi-
Table 1.  Patient characteristics
n (%) or
medians (IQR)
Total patients 63 (100)
Females 43 (68)
Age, years 62 (53; 71)
pPH classification
Idiopathic PAH 
Associated PAH
Chronic thromboembolic pPH
34 (54)
10 (16)
19 (30)
WHO functional class
II
III
IV
24 (38) 
31 (49)
8 (13)
BMI 26 (23; 29)
Mean pulmonary arterial pressurea, mm Hg 41 (30; 51)
Pulmonary vascular resistancea, dynsm–5 571 (331; 793)
Cardiac indexa, l/min/m2 2.6 (2.3; 3)
Mixed venous oxygen saturationa, % 64 (58; 68)
Tricuspid pressure gradient, mm Hg 60 (43; 80)
NT-pro-BNP (normal <130), ng/l 718 (221; 1,510)
6-min walking distance, m 455 (359; 534)
a Invasive hemodynamics obtained at the baseline diagnostic 
right heart catheterization.
Table 2.  Daytime and ambulatory overnight pulse oximetry and 
sleep studies
n (%) or me-
dians (IQR)
Ambulatory resting SpO2, % 95 (92; 96)
Daytime resting SpO2 ≥91% 55 (87)
Exercise SpO2 (end of 6MWT), % 88 (81; 95)
Median desaturation during exercise –5 (–11; –1)
Exercise desaturators (≥4% and absolute <90%) 33 (53)
Mean nocturnal SpO2, % 89 (85; 92)
Time spent with SpO2 <90%, % TIB 51 (13; 84)
>10% TIB with SpO2 <90% 49 (78)
>50% TIB with SpO2 <90% 33 (52)
ODI (≥4%), events/h 3 (1; 7)
ODI ≥10/h 10 (16)
AHIa, events/h 10 (6; 19)
AHI ≥10 events/ha 16 (50)
PBa, % TIB 9 (4; 13)
PB ≥10% TIBa 15 (47)
O DI = Oxygen desaturation index; AHI = apnea/hypopnea 
index; PB = periodic breathing.
a Thirty-two patients with simultaneous ambulatory cardio-
respiratory sleep study.
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 Fig. 1. The percentage of TIB spent with an 
Sp O 2  ! 90% is shown as a bar for every sin-
gle pPH patient.  
Table 3.  Differential characteristics of nocturnal nondesaturators, desaturators, and sustained desaturators
Nondesaturators Desaturators Sustained desaturators
Total patients 14 (22) 49 (76) 33 (52)
Females 9 (56) 34 (71) 21 (66)
Age, years 65 (40; 72) 61 (53; 71) 61 (54; 71)
pPH classification
Idiopathic PAH
Associated PAH
Chronic thromboembolic pPH
8 (53)
3 (20)
4 (26)
26 (54) 
7 (14) 
15 (31)
23 (72)
0
19 (28)
WHO functional class
II
III
IV
6 (43)
8 (57)
0 (7)
18 (37)
23 (47)
8 (16)
12 (38)
17 (53)
4 (12)
BMI 28 (26; 29) 26 (22; 29) 26 (23; 28)
Tricuspid pressure gradient, mm Hg 43 (38; 55) 66 (66; 50; 83)* 75 (58; 89)#, ‡
NT-pro-BNP (<130), ng/l 563 (240; 1,716) 718 (206; 1,371) 1,048 (206; 1,689)
6MWT, m 529 (385; 568) 450 (363; 506) 450 (367; 516)
Daytime resting SpO2, % 96 (95; 97) 94 (92; 96) 93 (91; 96)#
Exercise SpO2 (end of 6MWT), % 95 (89; 97) 87 (80; 91)** 86 (78; 91)#, ‡
Mean desaturation during exercise, % –2 (–7; 0) –6 (–11; –2)* –6 (–15; –2)
Exercise desaturators (≥4% and absolute <90%) 5 (33) 28 (58) 19 (59)
Mean nocturnal SpO2, % 94 (93; 95) 88 (85; 90)** 86 (84; 88)##, ‡
ODI, events/h 2 (1; 4) 3 (1; 9) 3 (1; 9)
ODI >10 events/h 0 10 (21)* 6 (20)
AHI, events/ha 9 (5; 18) 10 (6; 19) 10 (6; 19)
AHI >10 events/ha 3 (38) 13 (54) 8 (50)
PB, % TIBa 5 (4; 9) 11 (4; 13) 12 (5; 15)
PB ≥10 % of TIBa 3 (38) 12 (50) 9 (56)
V alues are numbers (%) or medians (IQR) unless otherwise 
stated. AHI = Apnea/hypopnea index; PB = periodic breathing; 
ODI = oxygen desaturation index. * p < 0.05 and ** p < 0.001 for 
desaturators vs. nondesaturators. # p < 0.05 and ## p < 0.001 for 
sustained desaturators vs. nonsustained desaturators (patients 
who spent less than 50% of their nighttime with an SpO2 <90%).
‡ p < 0.05 for between-group differences by analysis of variance for 
spending <10, 10–49, and ≥50% of the night with an SpO2 ≤90%.
a Thirty-two patients with simultaneous ambulatory cardio-
respiratory sleep study.
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cant correlation of age, WHO class, 6MWT, or pro-BNP 
with nocturnal desaturation.
 The positive predictive value of a daytime resting Sp O 2 
 6 91% to predict patients who would not be nocturnal 
desaturators was only 25%, corresponding to a very low 
sensitivity (16%; only 8 out of 49 patients with daytime 
Sp O 2  6 91% would not desaturate during TIB). For pa-
tients who did not desaturate during exercise, their risk 
of being a nocturnal desaturator was still 83%.
 Discussion 
 In the present study of patients diagnosed with PAH 
and CTEPH, we found that daytime Sp O 2 measurements 
do not reliably predict nocturnal Sp O 2 . Half of the pa-
tients spent more than half of their nighttime with an 
Sp O 2  ! 90%, and only a minority of the patients (25%) 
with a daytime resting Sp O 2  1 90% do not desaturate dur-
ing TIB. Nocturnal desaturation was significantly and 
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 Fig. 2. The correlations between the mean nocturnal Sp O 2 and the daytime resting Sp O 2 ( a ) and exercise Sp O 2 
at the end of a 6MWT ( b ) are shown. The correlations for both daytime assessments are relatively weak and 
nocturnal desaturation is found despite normal daytime Sp O 2 measures in the majority of patients. 
 Fig. 3. The correlations between the mean nocturnal Sp O 2 and the tricuspid pressure gradient ( a ) and time spent 
with an Sp O 2  ! 90% and the tricuspid pressure gradient ( b ) are shown. 
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independently correlated with the transtricuspid pres-
sure gradient, even when corrected for age, gender, day-
time Sp O 2 , NT-pro-BNP, and the 6MWT. These study re-
sults are important as they suggest that many pPH pa-
tients have nocturnal hypoxemia, a treatable condition 
associated with hemodynamic impairment in pPH. 
 Sleep poses profound physiological alterations to the 
respiratory system even in healthy subjects, which may 
lead to oxygen desaturation  [21] . Possible underlying 
mechanisms include alterations in ventilation-perfusion 
 [22] , a reduced functional residual capacity due to a re-
cumbent position, and reduced respiratory drive with rel-
ative alveolar hypoventilation  [8, 23] . In patients with 
preexisting lung or heart disease, these mechanisms may 
interact and promote sleep-related breathing disturbanc-
es. Oxygen deprivation in pulmonary vascular cells leads 
to vasoconstriction and consecutive elevation of the pul-
monary vascular resistance  [9, 24–26] . This mechanism 
might be deleterious in patients with preexisting pPH by 
augmenting the disease progression and pulmonary vas-
cular remodeling  [26] . Therefore, many guidelines rec-
ommend that patients with preexisting chronic lung dis-
eases be treated with supplemental oxygen if the daytime 
resting partial pressure of oxygen is  ^  8 kPa  [27, 28] . Al-
though oxygen administration acutely reduces pulmo-
nary vascular resistance in certain patients with PAH and 
CTEPH, data about the effect of long-term oxygen ther-
apy in pPH not associated with lung diseases is not avail-
able. In the absence of data from randomized controlled 
trials, current pPH guidelines base their recommenda-
tions for supplemental oxygen in PAH and CTEPH on old 
data available from cohorts of patients with pPH associ-
ated with chronic obstructive lung disease  [2, 18, 29] . 
Data on the prevalence, circadian occurrence, and clini-
cal correlates of hypoxemia in patients suffering from 
PAH and CTEPH are therefore highly warranted. 
 In our pPH collective we found a high prevalence of 
nocturnal desaturators, with more than three fourths of 
pPH patients spending  1 10% of their nighttime with an 
Sp O 2  ! 90%. Over 50% of patients even spent more than 
half of their night with a low Sp O 2 (sustained desatura-
tors). These findings corroborate findings in smaller co-
horts including patients with idiopathic PAH, where 70 
and 77%, respectively, were found to spend  1 10% of night 
with an Sp O 2  ! 90%  [7, 8] . Sustained nocturnal desatura-
tors were slightly less present in the cohort of Minai et al. 
 [8] (37%) compared to the current study (52%), although 
both populations had a comparable hemodynamic pro-
file. The reason for this difference is not clear. In our 
study nocturnal oxygen pulse oximetry was performed in 
the patients’ homes. The setting of pulse oximetry in the 
cohort of Minai et al.  [8] is not mentioned and it is not 
clear if their PAH cohort was allowed to use supplemental 
oxygen during nights as they were during the 6MWT. In 
addition, one third of the patients in our cohort had 
CTEPH. However, we found similar characteristics, oxy-
gen profiles, and proportions of nocturnal desaturators 
in PAH and CTEPH. We can therefore extend the strik-
ingly high percentage of nocturnal desaturators and sus-
tained desaturators to patients diagnosed with CTEPH. 
 Our pPH patients with nocturnal desaturation were 
not using supplemental oxygen. The majority had normal 
values of daytime resting Sp O 2  6 91% (55/63 patients; 
 fig. 1 ). Despite the preserved resting Sp O 2  6 91%, the ma-
jority (75%) had moderate-to-severe nocturnal hypox-
emia, i.e. they were desaturators or sustained desatura-
tors. A daytime resting Sp O 2  6 91% therefore had a very 
low positive predictive value for detecting nocturnal non-
desaturators (25%), and the diagnostic performance of 
daytime resting Sp O 2 in predicting nocturnal desatura-
tors was poor. Nocturnal hypoxemia may well be impor-
tant in pPH as it may worsen pulmonary hemodynamics. 
However, the significance of oxygen desaturation during 
sleep in pPH and other chronic lung diseases is not well 
studied. Sleep research in this field mainly focused on as-
sociated sleep apnea  [15, 30] ; however, nocturnal oxygen 
desaturation might be found even without significant 
sleep apnea  [8, 31] . In this study half of the patients un-
derwent simultaneous ambulatory cardiorespiratory 
sleep study. As might be expected, we found slightly more 
patients with sleep apnea among nocturnal desaturators; 
however, the difference was not significant. Almost half 
of the nocturnal desaturators did not fulfill the criteria 
for sleep apnea or periodic breathing. In this regard our 
data coincided with other reports describing markedly 
reduced nocturnal Sp O 2 in patients with preexisting lung 
diseases without sleep apnea  [8, 30] . Furthermore, the 
herein reported mean nocturnal Sp O 2 during sleep might 
even underestimate the real oxygen desaturation during 
sleep, as we did not include electroencephalogram for 
sleep staging and we can therefore not exclude that dur-
ing some investigated periods patients were awake in bed. 
Whether oxygen therapy would have any impact on per-
formance, disease progression, and quality of life in noc-
turnal desaturators with pPH is not known to date. Vari-
ous national and international guidelines recommend 
prescribing supplemental oxygen in patients with preex-
isting lung disease if a daytime resting oxygen partial 
pressure (Pa O 2 )  ^  8 kPa ( ^  60 mm Hg) and right heart 
strain are present  [28, 32, 33] . These recommendations 
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are mainly based on data available from a cohort of pa-
tients with COPD. For other chronic lung diseases such 
as parenchymal lung diseases, cystic fibrosis, or pPH the 
evidence for long-term oxygen therapy is even more lim-
ited and data on supplemental oxygen for those who de-
saturate only during exercise and/or sleep are scarce. Sup-
plemental oxygen has been shown to increase exercise ca-
pacity in parenchymal lung disease and cystic fibrosis 
 [34, 35] ; data on pPH and nocturnal oxygen therapy is not 
available. Controlled studies in this field are imperative, 
as overuse of supplemental oxygen might also be harmful 
as has been recently described for acute exacerbations of 
COPD  [36] . 
 We found a strong negative correlation of nocturnal 
desaturation with the tricuspid pressure gradient. This 
strong correlation persisted in multivariate models cor-
recting for age, exercise capacity, and resting Sp O 2 . There-
fore, the risk of being a nocturnal desaturator increases 
with hemodynamic disease severity. It may well be that 
pulmonary hemodynamics and nocturnal hypoxemia 
have a vicious mutually reinforcing relation. 
 In summary, we found in the hitherto largest pPH col-
lective including PAH and CTEPH that nocturnal oxy-
gen desaturation is highly prevalent, underestimated by 
daytime assessments and independently associated with 
hemodynamic disease severity. Therefore, we suggest 
that nocturnal pulse oximetry be included in the diag-
nostic pPH algorithm and that the potential benefit of 
supplemental oxygen in nocturnal desaturator be evalu-
ated in future studies. 
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